Robert Shumaker

2.4k total citations · 3 hit papers
38 papers, 1.8k citations indexed

About

Robert Shumaker is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Robert Shumaker has authored 38 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 12 papers in Oncology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Robert Shumaker's work include Plant Toxicity and Pharmacological Properties (6 papers), Hydrocarbon exploration and reservoir analysis (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Robert Shumaker is often cited by papers focused on Plant Toxicity and Pharmacological Properties (6 papers), Hydrocarbon exploration and reservoir analysis (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Robert Shumaker collaborates with scholars based in United States, United Kingdom and Netherlands. Robert Shumaker's co-authors include Corina E. Dutcus, Vicky Makker, Matthew H. Taylor, Daniel E. Stepan, Drew Rasco, Jane Wu, Perminder S. Sachdev, Emmett V. Schmidt, Allen Lee Cohn and James W. Mier and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and The Lancet Oncology.

In The Last Decade

Robert Shumaker

38 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

2019 360 citations Vicky Makker, Drew Rasco et al. The Lancet Oncology profile →
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

2020 359 citations Vicky Makker, Matthew H. Taylor et al. Journal of Clinical Oncology profile →
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors

2020 306 citations Matthew H. Taylor, Chung‐Han Lee et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Robert Shumaker

Since Specialization

Citations

This map shows the geographic impact of Robert Shumaker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Shumaker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Shumaker more than expected).

Fields of papers citing papers by Robert Shumaker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Shumaker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Shumaker. The network helps show where Robert Shumaker may publish in the future.

Co-authorship network of co-authors of Robert Shumaker

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Shumaker. A scholar is included among the top collaborators of Robert Shumaker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Shumaker. Robert Shumaker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer breakdown → 2020 ·Journal of Clinical Oncology ·Vicky Makker, Matthew H. Taylor, Carol Aghajanian, Ana Oaknin, James W. Mier, Allen Lee Cohn, Margarita Romeo, Raquel Bratos, Marcia S. Brose, Christopher DiSimone, Mark Messing, Daniel E. Stepan, Corina E. Dutcus, Jane Wu, Emmett V. Schmidt, Robert Orlowski, Perminder S. Sachdev, Robert Shumaker, Antonio Casado	359
2	Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors breakdown → 2020 ·Journal of Clinical Oncology ·Matthew H. Taylor, Chung‐Han Lee, Vicky Makker, Drew Rasco, Corina E. Dutcus, Jane Wu, Daniel E. Stepan, Robert Shumaker, Robert J. Motzer	306
3	Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial breakdown → 2019 ·The Lancet Oncology ·Vicky Makker, Drew Rasco, Nicholas J. Vogelzang, Marcia S. Brose, Allen Lee Cohn, James W. Mier, Christopher Di Simone, David M. Hyman, Daniel E. Stepan, Corina E. Dutcus, Emmett V. Schmidt, Matthew Guo, Perminder S. Sachdev, Robert Shumaker, Carol Aghajanian, Matthew H. Taylor	360
4	Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer 2018 ·Cancer Chemotherapy and Pharmacology ·Seiichi Hayato, Robert Shumaker, Jim Ferry, (unknown), Corina E. Dutcus, Ziad Hussein	18
5	Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor 2017 ·European Journal of Drug Metabolism and Pharmacokinetics ·Ziad Hussein, Hitoshi Mizuo, Seiichi Hayato, Masayuki Namiki, Robert Shumaker	58
6	Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison 2016 ·Investigational New Drugs ·Anne-Charlotte Dubbelman, Cynthia M. Nijenhuis, Robert S. Jansen, Hilde Rosing, Hitoshi Mizuo, (unknown), David Critchley, Robert Shumaker, Jan H.M. Schellens, Jos H. Beijnen	13
7	Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma 2015 ·Clinical Cancer Research ·David S. Hong, Razelle Kurzrock, Jennifer J. Wheler, Aung Naing, Gerald S. Falchook, Siqing Fu, Kevin B. Kim, Michael A. Davies, Ly M. Nguyen, Goldy C. George, Lucy T. Xu, Robert Shumaker, Min Ren, (unknown), Cynthia Bedell, Corina Andresen, Perminder S. Sachdev, James P. O'Brien, John Nemunaitis	57
8	Influence of hepatic impairment on lenvatinib pharmacokinetics following single‐dose oral administration 2014 ·The Journal of Clinical Pharmacology ·Robert Shumaker, Jagadeesh Aluri, Jean Fan, (unknown), Helen S. Pentikis, Min Ren	49
9	Pharmacokinetics and excretion of 14C-lenvatinib in patients with advanced solid tumors or lymphomas 2014 ·Investigational New Drugs ·Anne-Charlotte Dubbelman, Hilde Rosing, Cynthia M. Nijenhuis, Alwin D. R. Huitema, Marja Mergui‐Roelvink, Anubha Gupta, David Verbel, Gary A. Thompson, Robert Shumaker, Jan H.M. Schellens, Jos H. Beijnen	49
10	Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers 2014 ·Cancer Chemotherapy and Pharmacology ·Robert Shumaker, Meijian Zhou, Min Ren, Jean Fan, (unknown), Jagadeesh Aluri, Börje Darpö	32
11	Development and validation of LC–MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices 2012 ·Journal of Chromatography B ·Anne-Charlotte Dubbelman, Hilde Rosing, Bram Thijssen, (unknown), (unknown), (unknown), Robert Shumaker, Jan H.M. Schellens, Jos H. Beijnen	37
12	Model‐based treatment optimization of a novel VEGFR inhibitor 2012 ·British Journal of Clinical Pharmacology ·Ron J. Keizer, Anubha Gupta, Robert Shumaker, Jos H. Beijnen, Jan H.M. Schellens, Alwin D. R. Huitema	16
13	Abstract C116: Lenvatinib (E7080) does not prolong the QTc interval: Results from a thorough QT study in healthy volunteers. 2011 ·Molecular Cancer Therapeutics ·Robert Shumaker, Meijian Zhou, Min Ren, Jean Fan, (unknown), Börje Darpö	3
14	Reinterpreted Oriskany structure at the North Summit field, Chestnut Ridge anticline, Pennsylvania 2002 ·AAPG Bulletin ·Robert Shumaker	3
15	Evaluation of the Potential Interaction Between Felbamate and Erythromycin in Patients with Epilepsy 1998 ·The Journal of Clinical Pharmacology ·Rǎjesh C. Sachdeo, (unknown), (unknown), Robert Shumaker, James L. Perhach, William H. Lyness, A. Rosenberg	6
16	Tolerability and Pharmacokinetics of Monotherapy Felbamate Doses of 1,200–6,000 mg/day in Subjects with Epilepsy 1997 ·Epilepsia ·Rajesh Sachdeo, (unknown), Robert Shumaker, James L. Perhach, William H. Lyness, A. Rosenberg	13
17	Simultaneous Determination of Felbamate, Primidone, Phenobarbital, Carbamazepine, Two Carbamazepine Metabolites, Phenytoin, and One Phenytoin Metabolite in Human Plasma by High-Performance Liquid Chromatography 1994 ·Therapeutic Drug Monitoring ·Leslie Romanyshyn, J. K. Wichmann, N. Kucharczyk, Robert Shumaker, (unknown), R. Duane Sofia	40
18	The effect of felbamate on valproic acid disposition 1994 ·Clinical Pharmacology & Therapeutics ·Mary Wagner, Nina M. Graves, Ilo E. Leppik, Rory P. Remmel, Robert Shumaker, (unknown), James L. Perhach	40
19	Mltidose: A Multiple-Dose Simulation Program for Linear Systems Characterized by Exponential Functions 1989 ·Drug Metabolism Reviews ·Gary A. Thompson, Robert Shumaker	11
20	Human trophoblast xenografts in athymic mice: A model for peripheral aromatization 1989 ·Journal of Steroid Biochemistry ·J. O'Neal Johnston, C. Lee Wright, Robert Shumaker	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact